Research programme: induced pluripotent stem cell therapeutics - BlueRock Therapeutics
Alternative Names: Authentic cell replacement therapies - BlueRock TherapeuticsLatest Information Update: 28 Sep 2023
Price :
$50 *
At a glance
- Originator BlueRock Therapeutics
- Developer BlueRock Therapeutics; Memorial Sloan-Kettering Cancer Center
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Dopaminergic cell replacements; Glial cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cardiovascular disorders; Inborn genetic disorders; Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Inborn genetic disorders in Canada (Parenteral)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Parkinson's-disease in Canada (Parenteral)
- 28 Oct 2022 No recent reports of development identified for research development in Autoimmune-disorders in Canada